Navigation Links
Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
Date:5/22/2008

Presentation Will be Webcast Live and Archived on Company's Website

ROCKVILLE, Md., May 22 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced that Mihael H. Polymeropoulos, M.D., Vanda President and CEO will deliver a corporate presentation on Wednesday, May 28, 2008, at 9:00 a.m. Eastern Time.

The presentation will take place as part of the FBR Capital Markets 12th Annual Spring Investor Conference at the Grand Hyatt, New York, New York. Dr. Polymeropoulos' remarks will be available live on the Vanda Website, where it also will be archived for 30 days.

To access the presentation, log on to http://www.vandapharma.com and click on the Presentations option in the Investor Relations section. Please connect to the website several minutes prior to the start of the live presentation.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates. Vanda's lead product candidate, Fanapta(TM) (iloperidone), for which Vanda has recently submitted an NDA to the FDA, is a compound for the treatment of schizophrenia. Vanda's second product candidate, tasimelteon (VEC-162), is a compound for the treatment of sleep and mood disorders, which is currently in Phase III for chronic primary insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness in Phase II. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Vanda Pharmaceuticals to Present at Natixis Bleichroeders Hidden Gems Conference
2. Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting
3. Vanda Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 8, 2007
4. Vanda Pharmaceuticals VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties
5. Vanda Pharmaceuticals Announces that it No Longer Intends to Offer Convertible Senior Notes
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... “God's Miracle Man: Against All Odds”: an ... of published author, Keith C. A. Tucker, son of Minister Delores Pinnock and a ... by Reverend Mark Hardy , “While sitting up in bed, I felt a pounding ...
(Date:1/19/2017)... ... January 19, 2017 , ... Next week after January 20th, the fear ... political games that circumvent health needs of over 30 million. Many interviews with Dr. ... and needs government public servants were suppose to prioritize. Interviews provided below. ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... This month, ... announced that the name of their drug rehab center in Delray Beach, Florida has ... recognize that not only stars such as Philip Seymour Hoffman and Chris Farley are ...
(Date:1/19/2017)... New York (PRWEB) , ... January 19, 2017 ... ... high definition dynamic telemedicine solutions, has recently unveiled impressive transportable capabilities with their ... newly designed product is an extension to RMT technology that delivers HD, dynamic, ...
(Date:1/19/2017)... ... January 19, 2017 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it will be co-hosting ... in innovative excipients and drug delivery solutions to health industries worldwide. The one ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Pfizer joins Astex, AstraZeneca, ... Consortium   Major research investment to ...   The Milner Therapeutics Institute today ... a partner to the Milner Therapeutics Consortium. Pfizer has ... transfer of materials between industry and academia and allocation ...
(Date:1/19/2017)... , January 19, 2017 The global  pacemaker market ... report by Grand View Research, Inc. The heightening prevalence of cardiac conditions coupled ... growth of Pacemaker globally. In addition, technological enhancements in these devices are supporting ... ... Grand View Research Logo ...
(Date:1/19/2017)... LONDON , Jan. 18, 2017 The ... provides understanding and access to partnering deals and agreements ... - Trends in partnering deals - Top deals by ... stage of development, technology type The report provides ... entered into by the world,s leading healthcare companies. ...
Breaking Medicine Technology: